Literature DB >> 21335479

Prognostic implications of diuretic dose in chronic heart failure.

João Martins1, Patrícia Lourenço, José Paulo Araújo, Joana Mascarenhas, Ricardo Lopes, Ana Azevedo, Paulo Bettencourt.   

Abstract

BACKGROUND: Prognostic implications of diuretics dose are not completely understood. We aim to study the association between diuretic doses and long-term prognosis in patients with chronic stable heart failure (HF). METHODS AND
RESULTS: We conducted a retrospective cohort study of 244 patients followed at an outpatient HF clinic. Admission criteria were clinical stability in the previous 3 months and optimized medical therapy. Demographic characteristics, clinical, and laboratory parameters were recorded. Patients were followed for 2 years and the outcome was defined as all-cause death or hospital admission due to HF worsening. Patients on ≤ 80 mg furosemide were compared with those on higher doses. Patients were grouped according to furosemide dose (≤ 80 mg and >80 mg/d) and according to volemia as assessed by the sodium retention score: <3 (euvolemia) versus ≥ 3 (hypervolemia). Patients on higher diuretic doses (n = 79) were older, more hypervolemic, and more symptomatic. Patients on >80 mg furosemide had a higher risk of death or hospital admission (hazard ratio [HR]: 2.07, 95% confidence interval [CI]: 1.37-3.1). For each 40-mg furosemide tablet, there was a 67% increase in risk of an adverse outcome within 2 years. The increase in risk was independent of other variables crudely associated with prognosis. Among euvolemic patients, those on ≤ 80 mg/d furosemide performed better than those on higher doses. Among hypervolemic patients, the diuretic dose had no prognostic implications.
CONCLUSIONS: Higher diuretic doses associated strongly and independently with adverse long-term outcome in chronic HF. Possibly, in euvolemic patients, efforts should be made to reduce diuretic dose.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21335479     DOI: 10.1177/1074248410388807

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  5 in total

1.  Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors.

Authors:  João Pedro Ferreira; Mário Santos; Sofia Almeida; Irene Marques; Paulo Bettencourt; Henrique Carvalho
Journal:  Clin Res Cardiol       Date:  2013-07-10       Impact factor: 5.460

Review 2.  Loop diuretics in chronic heart failure: how to manage congestion?

Authors:  Justas Simonavičius; Christian Knackstedt; Hans-Peter Brunner-La Rocca
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

Review 3.  Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?

Authors:  Brian Kerr; Rebabonye B Pharithi; Matthew Barrett; Carmel Halley; Joe Gallagher; Mark Ledwidge; Kenneth McDonald
Journal:  Int J Heart Fail       Date:  2021-02-25

4.  Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction.

Authors:  Stefano Coiro; Nicolas Girerd; John J V McMurray; Bertram Pitt; Karl Swedberg; Dirk J van Veldhuisen; Zohra Lamiral; Patrick Rossignol; Faiez Zannad
Journal:  Clin Res Cardiol       Date:  2021-05-06       Impact factor: 5.460

5.  Dose of furosemide before admission predicts diuretic efficiency and long-term prognosis in acute heart failure.

Authors:  Zorba Blázquez-Bermejo; Nuria Farré; Pedro Caravaca Perez; Marc Llagostera; Laura Morán-Fernández; Aleix Fort; Javier de Juan Bagudá; María Dolores García-Cosio; Sonia Ruiz-Bustillo; Juan F Delgado
Journal:  ESC Heart Fail       Date:  2021-11-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.